Marc Tessier-Lavigne insider trades

Open-market stock purchases and sales by Marc Tessier-Lavigne, Director at Denali Therapeutics Inc, from SEC Form 4 filings since Nov 18, 2011.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +79%.

Recent trades

No open-market trades in the last 12 months.

Companies traded

  • DNLI Denali Therapeutics Inc: 41 sales, last Jun 3, 2025
  • REGN Regeneron Pharmaceuticals, Inc: 55 sales, last Jan 3, 2023
  • AGIO Agios Pharmaceuticals Inc: 1 buy, last Jun 21, 2016
  • JUNO Juno Therapeutics, Inc: other filings, last Jun 17, 2016
  • PFE Pfizer Inc: other filings, last Apr 23, 2015

Get free alerts when Marc Tessier-Lavigne files a new trade →